PDCD1 and extranodal nasal NK/T cell lymphoma: In the phase 2 single-arm ORIENT-4 trial [58], monotherapy with the anti-PD-1 mAb sintilimab demonstrated 75.0% ORR and 78.6% 2-year OS in 28 patients with r/r NKTCL.